The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates
Abstract
Immunogenicity can be a major obstacle to successful protein drug therapy. Antidrug antibodies may neutralize therapeutic function, influence pharmacokinetics and, in some cases, lead to severe adverse effects. These effects depend on factors including dose, regimen, delivery route and contaminants, among others. Importantly, immunogenicity is a consideration that is better addressed during preclinical development before complications arise in clinical trials or following licensure. This article will address the development and application of computational tools for immunogenicity assessment of protein therapeutics, and validation of those predictions using peripheral blood from exposed subjects or alternative in vivo methods.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite these challenges, there are efforts aimed at predicting immunogenicity using in silico and in vitro tools.49”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [49]
Citations
Cites
NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells
Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M., Hioki, K., Ueyama, Y., Koyanagi, Y., Sugamura, K., Tsuji, K., et al. (2002) · Blood · doi:10.1182/blood-2001-12-0207 · Cited by 1,483
Natural versus adaptive regulatory T cells
Bluestone, J. A., & Abbas, A. K. (2003) · Nature reviews. Immunology · doi:10.1038/nri1032 · Cited by 1,319
Casadevall, N., Nataf, J., Viron, B. M., Kolta, A. M., Kiladjian, J., Martin-Dupont, P., Michaud, P. A., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,244
Multiple defects in innate and adaptive immunologic function in NOD/LtSz- scid mice.
Shultz, L. D., Schweitzer, P. A., Christianson, S. W., Gott, B., Schweitzer, I. B., Tennent, B. J., McKenna, S., Mobraaten, L. E., Rajan, T. V., Greiner, D. L., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.180 · Cited by 1,224
Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice
Traggiai, E., Chicha, L., Mazzucchelli, L., Bronz, L., Piffaretti, J.-C., Lanzavecchia, A., & Manz, M. G. (2004) · Science · doi:10.1126/science.1093933 · Cited by 989
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice
Ishikawa, F., Yasukawa, M., Lyons, B. L., Yoshida, S., Miyamoto, T., Yoshimoto, G., Watanabe, T., Akashi, K., Shultz, L. D., & Harada, M. (2005) · Blood · doi:10.1182/blood-2005-02-0516 · Cited by 933
Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires
Southwood, S., Sidney, J., Kondo, A., del Guercio, M., Appella, E., Hoffman, S. L., Kubo, R. T., Chesnut, R. W., Grey, H. M., & Sette, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3363 · Cited by 665
Immunogenicity of protein therapeutics
Groot, A. S. D., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 544
Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”
Groot, A. S. D., Moise, L., McMurry, J. A., Wambre, E. R., Overtvelt, L. V., Moingeon, P. E., Scott, D. W., & Martin, W. D. (2008) · Blood · doi:10.1182/blood-2008-02-138073 · Cited by 392
Self-citationA Novel Mechanism of Action for Anti-Thymocyte Globulin
Lopez, M., Clarkson, M. R., Albin, M., Sayegh, M. H., & Najafian, N. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050422 · Cited by 365
Cited by
Sorted by citations
Stability of Protein Pharmaceuticals: An Update
Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010) · Pharmaceutical Research · doi:10.1007/s11095-009-0045-6 · Cited by 1,140
The immunogenicity of humanized and fully human antibodies
Harding, F., Stickler, M. M., Razo, J., & DuBridge, R. B. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 743
Immunogenicity of Therapeutic Protein Aggregates
Moussa, E. M., Panchal, J. P., Moorthy, B. S., Blum, J. S., Joubert, M. K., Narhi, L. O., & Topp, E. M. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.002 · Cited by 525
Monoclonal antibody therapeutics: history and future
Buss, N. A. P. S., Henderson, S. J., McFarlane, M., Shenton, J. M., & de Haan, L. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.08.001 · Cited by 480
Dimitrov, D. S. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-921-1_1 · Cited by 384
Metadata
- Authors
- DEGROOT, A., MCMURRY, J., & MOISE, L.
- Affiliations
- University of Rhode Island (US)
- Corresponding author
- DEGROOT, A
- MOISE, L
- ORCID
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 8
- Issue
- 5
- Pages
- 620-626
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W2092720388
- Cited by
- 109
- References
- 55
- Citations by year
- 2026: 4 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 10 · 2017: 5 · 2016: 2 · 2015: 5 · 2014: 4 · 2013: 6 · 2012: 14
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- immunogenicity prediction, therapeutic proteins, antidrug antibodies, in silico prediction tools, preclinical drug development, pharmacokinetics, adverse drug reactions, neutralizing antibodies
- MeSH terms
- Animals, Epitopes, B-Lymphocytes, Computer Simulation, Drug Evaluation, Preclinical, Humans, Mice, Transgenic, Recombinant Proteins, T-Lymphocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
